ClinicalTrials.gg
CompletedNCT03455842AURORAUpdated Nov 18, 2021

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis

A Phase 2 interventional study of BCD-089, 162 mg, s/c, qw and BCD-089, 162 mg, s/c, q2w in Seropositive RA, sponsored by Biocad. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-18.

Sponsored by Biocad · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study is Phase II randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety, pharmacokinetics and pharmacodynamics of 2 dosing regimens (qw and q2w, s/c) of monoclonal antibody to IL6R (BCD-089) in patients with active rheumatoid arthritis and inadequate response to methotrexate.

Read the detailed description

IL-6 is a new potential therapeutic target which plays important role in pathogenesis of several autoimmune disorders including rheumatoid arthritis. BCD-089 is a novel fully human monoclonal antibody against the interleukin-6 receptor developed by JCS BIOCAD (Russia) which is successfully passed phase I clinical study. Fixed dose of 162 mg was chosen for evaluation in phase II clinical trial. Comparisons in terms of efficacy, safety, PK/PD will be made for every week and every other week dosing for 54 weeks. W0-W12, planed as blinded, "main" period of the study, consists of three arms (n=35, each) - 2 study arms and placebo arm and served to test the hypothesis of superiority of BCD-089 to placebo. W12-W54, planned as "open" period of the study and served to evaluate long-therm safety and efficacy of BCD-089 in patients with active rheumatoid arthritis.

02

Conditions studied

  • Seropositive RA
03

In context

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Males and females aged 18 - 80 years, at IC signing date.
  3. Diagnosis of rheumatoid arthritis, according to ACR 2010 criteria, at least for 6 month prior to IC signing date.
  4. Active rheumatoid arthritis at IC signing date.
  5. Therapy with methotrexate for at least 3 month prior to IC signing date.
  6. Stable dose of methotrexate (10-25 mg/week) for 4 weeks prior to IC signing date.
  7. Persistent activity of RA despite methotrexate (provided by Sponsor) therapy within screening period (4-6weeks).
  8. Patients, with following parameters of laboratory investigations:

    • ≥ 80 g/l;
    • White blood cells ≥ 3,0×109/l;
    • ≥ 100×109/l;
    • Neutrophils ≥ 2×109/l;
    • and AST \< 1,5 × UNL (according to the local / central laboratory normal values)
    • Serum creatinine \< 1,7 × UNL (according to the local / central laboratory normal values)
  9. Negative urine pregnancy test for women at screening (only for women with - not applied to women at menopause for at least 2 years or surgically sterilized).
  10. Patients ability to follow the protocol procedures (according to PI opinion)
  11. Patient and his/her sexual partner with childbearing potential are ready to use reliable , starting at the date of IC sign, within the study period and 4 weeks after the last dose of drug administration. (Not applied to participants/sexual partners who surgically sterilized, and women at menopause for more than 2 years). Reliable contraception considered as 1 barrier method and one of the following: spermicides, oral contraception or intrauterine devices)

Exclusion criteria

Exclusion Criteria:

    1. History of therapy with tocilizumab or other monoclonal antibodies to IL6R / IL6.

      1. History of therapy with rituximab or other B-cell depleting medicines. 3. Felty's syndrome (any form). 4. ACR1991 functional status IV. 5. Low disease activity of rheumatoid arthritis (DAS28-CRP(4) \< 3,2). 6. Known allergy or intolerance of any drug/placebo ingredients.
      1. Concomitant medication including any of the following:
      • Requirement > 10 mg / day of oral prednisolone (or equivalent);
      • Requirement \< 10 mg / day of oral prednisolone (or equivalent), if the dose was not stable for 4 weeks prior the date of sign (it is allowed to include patients on topical );
      • Requirement of NSAID, if dose was not stable for 4 weeks prior the date of informed consent sign (it is allowed to include patients received NSAID occasionally to treat intercurrent fever or allergy).
      • Intake of alkalizing agents at any time during 12 month prior the date of IC sign.
      • Intraarticular administration of steroids within 4 month prior the date of IC sign
      • Vaccination with live or attenuated vaccines at any time during 8 weeks preceding the date of IC sign 8. Leflunomide intake within 8 weeks prior the date of IC sign. 9. Therapy with TNF inhibitors, JAK-inhibitors, T-lymphocyte co-stimulation blockers within 2 month prior to the date of IC sign.

        1. Diagnosis or history of severe immunodeficiency. 11. , , , Syphilis. 12. Diagnosis or history of tuberculosis. 13. Latent TB (positive Diaskin test® or QuantiFERON®-TB Gold or T-SPOT.TB or Mantoux/PPD with lack of TB signs on chest X-ray).
        1. It is allowed to include patients with inconclusive Diaskin test® or QuantiFERON®-TB Gold or T-SPOT.TB or Mantoux/PPD, providing that TB has been ruled out (and documented) by TB-specialist (Phtisyatrician) 15. It is allowed to include patients with positive Mantoux/PPD with no signs of TB on chest X-ray, providing that Diaskin test® or QuantiFERON®-TB Gold or T-SPOT.TB was additionally made with negative results and TB has been ruled out (and documented) by TB-specialist (Phtisyatrician) 16. History of Herpes Zoster. 17. Documented chicken pox within 30 days prior to IC sign 18. Diagnosis of any other chronic infection (sepsis, invasive mycosis, histoplasmosis etc.), which may increase the risk of infectious adverse events.
        1. Any acute infection or chronic infection flare within 30 days prior to informed consent sign, which may increase (according to the PI opinion) the risk of infectious adverse events.
        1. Severe infections (required hospitalization, systemic antimicrobial/antifungal/antiviral treatment) within 6 months prior to date of IC sign.
        1. Systemic antimicrobial, antifungal, antiviral or anthelminthic medication within 2 months prior to fate of IC date.
        1. More than 4 cases of acute respiratory infections within 6 month prior to IC date.
        1. Major surgical interventions within 30 days prior to IC date or planned surgical intervention within the period of the study participation.
        1. History of seizures. 25. History of depression, suicidal ideation/behavior. 26. Diverticulosis or diverticulitis. 27. Known history of alcohol or drug abuse, or signs of alcohol/drug dependence at present time, which according to the PI opinion could interfere with RA treatment or reduce compliance.
        1. Any other documented conditions which increase the risk of AEs development or may interfere with symptoms of RA (masking, increasing or changing) or induce clinical symptoms or laboratory abnormalities similar to RA:
        2. Uncontrolled diabetes mellitus;
        3. Severe, uncontrolled hypertonia;
        4. Presence or history of inflammatory joint disease other than RA (ankylosing spondylitis, gout, psoriatic arthritis, Lyme disease) or any other systemic disease (including lupus, Crohn's disease, ulcerative colitis, scleroderma, inflammatory myopathy, mixed connective tissue disease, autoimmune overlap syndrome, fibromyalgia etc.);
        5. Any history of , excluding cured basal cell carcinoma / cervical cancer in situ (complete remission for 5 years); cured basal cell skin carcinoma (5 years complete remission), cured ductal breast cancer (5 years complete remission);
        6. Decompensated liver or kidney diseases;
        7. Unstable angina pectoris;
        8. Chronic heart failure, class III-IV according to ;
        9. Myocardial infarction, within 1 year prior to IC sign;
        10. History of organ transplantation;
        11. History of Quincke edema; History of any significant respiratory diseases, including , asthma or bronchiectasis disease;
        12. Decompensated respiratory failure;
        13. History of multiple sclerosis, Devic's disease, or Guillain-Barre syndrome;
        14. Any neurological disease with motor or sensory functions impairment. 29. Pregnancy, current or planned in less than 8 weeks after study completion or breastfeeding.

          1. Simultaneous participation in other clinical trials or participation in other clinical trials with 3 month prior to IC signing date or history of participation it current clinical study (excluding patients dropped out at screening).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    BCD-089 weekly

    Biological: BCD-089, 162 mg, s/c, qw

  • Experimental
    BCD-089 biweekly

    Biological: BCD-089, 162 mg, s/c, q2w

  • Placebo comparator
    Placebo

    Drug: placebo

Interventions

  • BiologicalBCD-089, 162 mg, s/c, qw

    Drug page: Levilimab

    Subcutaneous injections of anti-IL6R every week

  • BiologicalBCD-089, 162 mg, s/c, q2w

    Drug page: Levilimab

    Subcutaneous injections of anti-IL6R every other week

  • Drugplacebo

    Subcutaneous injections of placebo every week, until week 12. Thereafter subcutaneous injections of anti-IL6R every other week

06

What researchers measure

Primary outcomes

  1. ACR20

    Time frame: week 12

Secondary outcomes

  1. ACR50

    Time frame: week 4, week 8, week 16, week 24, week 36, week 48, week 52

  2. ACR70

    Time frame: week 4, week 8, week 16, week 24, week 36, week 48, week 52

  3. Low RA activity

    DAS28-CRP(4)\<3.2

    Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 48, week 52

  4. Low RA activity

    SDAI = 11 or less

    Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 48, week 52

  5. Low RA activity

    CDAI = 10 or less

    Time frame: week 4, week 8, week 12, week 16, week 24, week 36, week 48, week 52

  6. RA remission

    According to the ACR/EULAR 2011 remission criteria

    Time frame: week 24, week 36, week 48, week 52

  7. X-ray signs of RA

    Time frame: week52

  8. Pharmacokinetics of BCD-089

    Area Under the BCD-089 Plasma Concentration Versus Time Curve \[AUC0-last\]

    Time frame: week 0 - week 12

  9. Pharmacokinetics of BCD-089

    Peak Plasma Concentration \[Cmax\]

    Time frame: week 0 - week 12

  10. Pharmacokinetics of BCD-089

    Minimum Plasma Concentration \[Cmin\]

    Time frame: week 0 - week 12

  11. Pharmacokinetics of BCD-089

    Time to Maximum Plasma Concentration \[Tmax\]

    Time frame: week 0 - week 12

  12. Pharmacokinetics of BCD-089

    Time to Minimum Plasma Concentration \[Tmin\]

    Time frame: week 0 - week 12

  13. Pharmacokinetics of BCD-089

    Accumulation Ratio \[AR\]

    Time frame: week 0 - week 12

  14. Pharmacodynamics of BCD-089

    Plasma concentration of CRP

    Time frame: week 0 - week 12

  15. Pharmacodynamics of BCD-089

    Plasma concentration of Interleukin-6

    Time frame: week 0 - week 12

  16. Pharmacodynamics of BCD-089

    Plasma concentration of soluble receptor of interleukin-6

    Time frame: week 0 - week 12

  17. Pharmacodynamics of BCD-089

    Plasma concentration of tumor necrosis factor - alpha

    Time frame: week 0 - week 12

07

Study locations

4 sites
  • 1st City Clinical Hospital
    Minsk, Belarus
  • Chelyabinsk Regional Clinical hospital
    Chelyabinsk, Russian Federation
  • Kazan State Medical University
    Kazan, Russian Federation
  • North-Western State Medical University n.a. I.I.Mechnikov
    Saint Petersburg, Russian Federation
08

References and documents

Publications

  • Mazurov V.I., Korolev M.A., Prystrom A.M., Kunder E.V., Soroka N.F., Kastanayan A.A., Povarova T.V., Plaksina T.V., Antipova O.V., Kretchikova D.G., Smakotina S.A., Tciupa O.A., Puntus E.V., Raskina T.A., Shilova L.N., Kropotina T.V., Nesmeyanova O.B., Popova T.A., Vinogradova I.B., Linkova Yu.N., Dokukina E.A., Plotnikova A.V., Pukhtinskaia P.S., Zinkina-Orikhan A.V., Eremeeva A.V., Lutckii A.A. Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR). Modern Rheumatology Journal. 2021;15(4):13-23. https://doi.org/10.14412/1996-7012-2021-4-13-23

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Dec 2018, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2018
First posted
Mar 7, 2018
StartActual
Feb 1, 2018
Primary completionActual
Dec 31, 2018
CompletionActual
Oct 22, 2019
Last update
Nov 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03455842
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Mar 7, 2018
Start date
Feb 1, 2018
Primary completion
Dec 31, 2018
Completion
Oct 22, 2019
Last update
Nov 18, 2021

Study contacts

Roman Ivanov, PhD
study chair · Biocad

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levilimab

Start the discussion